🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/08/1997 | 15,63 | 15,63 | 15,00 | 15,56 | +0,81% | 4,00% | 231.600 |
| 14/08/1997 | 15,25 | 15,50 | 15,13 | 15,44 | +2,49% | 2,46% | 284.200 |
| 13/08/1997 | 15,25 | 15,81 | 14,69 | 15,06 | +0,42% | 7,38% | 1.018.400 |
| 12/08/1997 | 16,25 | 16,25 | 14,69 | 15,00 | -5,88% | 9,62% | 1.685.200 |
| 11/08/1997 | 16,88 | 17,06 | 15,94 | 15,94 | -5,90% | 6,67% | 500.200 |
| 08/08/1997 | 16,81 | 17,00 | 16,63 | 16,94 | -0,37% | 2,23% | 257.600 |
| 07/08/1997 | 17,56 | 17,56 | 16,88 | 17,00 | -2,51% | 3,91% | 455.800 |
| 06/08/1997 | 17,63 | 17,63 | 17,25 | 17,44 | -0,62% | 2,13% | 129.600 |
| 05/08/1997 | 16,63 | 17,69 | 16,63 | 17,55 | +4,37% | 6,39% | 548.200 |
| 04/08/1997 | 17,00 | 17,00 | 16,06 | 16,81 | -1,10% | 5,51% | 577.000 |
| 01/08/1997 | 17,88 | 17,88 | 16,88 | 17,00 | -3,20% | 5,59% | 505.800 |
| 31/07/1997 | 17,44 | 17,81 | 17,38 | 17,56 | +1,08% | 2,51% | 633.800 |
| 30/07/1997 | 17,06 | 17,50 | 16,94 | 17,38 | +1,83% | 3,30% | 1.280.000 |
| 29/07/1997 | 18,31 | 18,56 | 16,94 | 17,06 | -6,51% | 8,87% | 2.165.800 |
| 28/07/1997 | 18,56 | 18,75 | 17,88 | 18,25 | -2,01% | 4,71% | 725.800 |
| 25/07/1997 | 18,63 | 19,44 | 18,38 | 18,63 | +0,68% | 5,70% | 454.800 |
| 24/07/1997 | 19,25 | 19,63 | 18,38 | 18,50 | -1,33% | 6,49% | 431.400 |
| 23/07/1997 | 18,63 | 19,38 | 18,50 | 18,75 | +2,39% | 4,70% | 467.600 |
| 22/07/1997 | 17,25 | 18,31 | 17,00 | 18,31 | +7,52% | 7,61% | 713.600 |
| 21/07/1997 | 17,38 | 17,50 | 16,88 | 17,03 | -2,68% | 3,60% | 1.084.200 |
| 18/07/1997 | 18,25 | 18,44 | 17,25 | 17,50 | -3,78% | 6,51% | 418.600 |
| 17/07/1997 | 18,56 | 18,63 | 18,00 | 18,19 | -2,02% | 3,37% | 564.600 |
| 16/07/1997 | 17,50 | 18,63 | 17,50 | 18,56 | +4,58% | 6,43% | 950.000 |
| 15/07/1997 | 18,00 | 18,25 | 17,38 | 17,75 | +7,17% | 4,86% | 1.880.400 |
| 14/07/1997 | 18,94 | 19,06 | 15,25 | 16,56 | -12,54% | 20,13% | 2.167.200 |
| 11/07/1997 | 19,06 | 19,44 | 18,63 | 18,94 | +0,66% | 4,26% | 769.200 |
| 10/07/1997 | 19,00 | 19,06 | 18,13 | 18,81 | +0,33% | 4,93% | 310.000 |
| 09/07/1997 | 18,50 | 19,75 | 18,50 | 18,75 | -4,08% | 6,76% | 1.110.600 |
| 08/07/1997 | 19,88 | 19,88 | 19,06 | 19,55 | -1,34% | 4,09% | 554.800 |
| 07/07/1997 | 20,50 | 20,75 | 19,69 | 19,81 | -1,71% | 5,18% | 662.400 |